Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease

Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease

Objective: To present a critical review of publications reporting on the rationale and clinical implications of the use of biomarkers for the early diagnosis of Alzheimer's disease (AD). Methods: We conducted a systematic search of the PubMed and Web of Science electronic databases, limited t...

Full description

Bibliographic Details
Main Authors:	Orestes V. Forlenza, Breno S. Diniz, Antonio L. Teixeira, Florindo Stella, Wagner Gattaz
Format:	Article
Language:	English
Published:	Associação Brasileira de Psiquiatria (ABP) 2013-09-01
Series:	Brazilian Journal of Psychiatry
Subjects:	Alzheimer's disease mild cognitive impairment biomarkers neuroimaging amyloid-β protein Tau protein
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462013000300284&lng=en&tlng=en

Similar Items

Longitudinal associations of apathy and regional tau in mild cognitive impairment and dementia: Findings from the Alzheimer's Disease Neuroimaging Initiative
by: Pranitha Y. Premnath, et al.
Published: (2024-01-01)

Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis
by: Zsolt Huszár, et al.
Published: (2024-04-01)

Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-𝜷 in mild cognitive impairment but not in Alzheimer’s disease
by: Feng Xing, et al.
Published: (2021-06-01)

A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer’s Disease
by: Yunxing Ma, et al.
Published: (2022-07-01)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
by: LEI Zhe, et al.
Published: (2022-07-01)

Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment
by: Giulia Arenare, et al.
Published: (2023-08-01)

Combining cognitive screening tests for the evaluation of mild cognitive impairment in the elderly
by: Rodolfo B. Ladeira, et al.
Published: (2009-01-01)

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
by: Alexa Pichet Binette, et al.
Published: (2022-03-01)

Based on Tau PET Radiomics Analysis for the Classification of Alzheimer’s Disease and Mild Cognitive Impairment
by: Fangyang Jiao, et al.
Published: (2023-02-01)

Exposure to Cadmium and Other Trace Elements Among Individuals with Mild Cognitive Impairment
by: Teresa Urbano, et al.
Published: (2024-12-01)

Interaction between Aβ and tau on reversion and conversion in mild cognitive impairment patients: After 2-year follow-up
by: Jinzhi Tang, et al.
Published: (2024-03-01)

Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis
by: Alex Zabala-Findlay, et al.
Published: (2023-04-01)

Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum
by: Kok Pin Ng, et al.
Published: (2022-09-01)

Neuroimaging and machine learning for studying the pathways from mild cognitive impairment to alzheimer’s disease: a systematic review
by: Maryam Ahmadzadeh, et al.
Published: (2023-08-01)

P-tau231 as a diagnostic biomarker for Alzheimer's Disease and mild cognitive impairment: A systematic review and meta-analysis
by: Fardin Nabizadeh, et al.
Published: (2022-01-01)

Language in Amnestic Mild Cognitive Impairment and Dementia of Alzheimer’s Type: Quantitatively or Qualitatively Different?
by: Regina Jokel, et al.
Published: (2019-03-01)

VRADA training system as a non-pharmacological dual intervention to alleviate symptoms of the pathophysiology of Mild Cognitive Impairment
by: Eleni E. Tzekaki, et al.
Published: (2023-09-01)

From Small Peptides to Large Proteins against Alzheimer’sDisease
by: Pasquale Picone, et al.
Published: (2022-09-01)

Relationship of Retinal Nerve Fibers Layer Thickness with Mild Cognitive Impairment and Alzheimer\'s Dementia
by: Siamak Akbarzadeh, et al.
Published: (2022-12-01)

The role of autophagy in Alzheimer's disease and its potential for therapy
by: Min LIU, et al.
Published: (2014-05-01)

Altered brain connectivity in mild cognitive impairment is linked to elevated tau and phosphorylated tau, but not to GAP-43 and Amyloid-β measurements: a resting-state fMRI study
by: Mohammad Sadeghi, et al.
Published: (2024-08-01)

Cognivue Clarity characterizes mild cognitive impairment and Alzheimer’s disease in biomarker confirmed cohorts in the Bio-Hermes Study
by: James E. Galvin, et al.
Published: (2024-10-01)

Biomarkers in Alzheimer’s disease
by: Janeiro Manuel H., et al.
Published: (2020-11-01)

Unraveling the Potential Underlying Mechanisms of Mild Behavioral Impairment: Focusing on Amyloid and Tau Pathology
by: Efthalia Angelopoulou, et al.
Published: (2024-07-01)

Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS)
by: Tyler S. Saunders, et al.
Published: (2022-09-01)

Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
by: Eliasz Engelhardt, et al.
Published: (2024-12-01)

Apathy and APOE in mild behavioral impairment, and risk for incident dementia
by: Daniella Vellone, et al.
Published: (2022-01-01)

Molecular Role of Protein Phosphatases in Alzheimer’s and Other Neurodegenerative Diseases
by: Mubashir Hassan, et al.
Published: (2024-05-01)

Editorial: The role of neuroimaging and neurostimulation in detecting and treating Alzheimer's disease and mild cognitive impairment
by: Arianna Menardi, et al.
Published: (2024-11-01)

Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
by: Mandić Gorana, et al.
Published: (2008-01-01)

Modeling Alzheimer’s Disease in <i>Caenorhabditis elegans</i>
by: Javier Alvarez, et al.
Published: (2022-01-01)

Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting
by: Malene Schjønning Nielsen, et al.
Published: (2016-10-01)

Associations of Serum Isoleucine with Mild Cognitive Impairment and Alzheimer’s Disease
by: Xiao-jun Jing, et al.
Published: (2024-09-01)

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
by: Zdeněk Fišar
Published: (2022-11-01)

Dreaming of a New World Where Alzheimer’s Is a Treatable Disorder
by: Marcella Catania, et al.
Published: (2019-11-01)

Deletion of Murine APP Aggravates Tau and Amyloid Pathologies in the 5xFADXTg30 Alzheimer’s Disease Model
by: Kunie Ando, et al.
Published: (2025-01-01)

Overview of the Molecular Modalities and Signaling Pathways Intersecting with β-Amyloid and Tau Protein in Alzheimer’s Disease
by: Ahmed M. Elshazly, et al.
Published: (2023-07-01)

From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias
by: Adalberto Studart-Neto, et al.
Published: (2022-08-01)

Quality of Life in Mild Cognitive Impairment and Mild Dementia Associated with Alzheimer’s Disease: A Systematic Review
by: Joanna Campbell, et al.
Published: (2024-11-01)

The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment
by: Hyung-Ji Kim, et al.
Published: (2022-07-01)